CONTEXT: The global significance of infective endocarditis (IE) caused by Staphylococcus aureus is unknown. OBJECTIVES: To document the international emergence of health care-associated S aureus IE and methicillin-resistant S aureus (MRSA) IE and to evaluate regional variation in patients with S aureus IE. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational cohort study set in 39 medical centers in 16 countries. Participants were a population of 1779 patients with definite IE as defined by Duke criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to December 2003. MAIN OUTCOME MEASURE: In-hospital mortality. RESULTS: S aureus was the most common pathogen among the 1779 cases of definite IE in the International Collaboration on Endocarditis Prospective-Cohort Study (558 patients, 31.4%). Health care-associated infection was the most common form of S aureus IE (218 patients, 39.1%), accounting for 25.9% (Australia/New Zealand) to 54.2% (Brazil) of cases. Most patients with health care-associated S aureus IE (131 patients, 60.1%) acquired the infection outside of the hospital. MRSA IE was more common in the United States (37.2%) and Brazil (37.5%) than in Europe/Middle East (23.7%) and Australia/New Zealand (15.5%, P<.001). Persistent bacteremia was independently associated with MRSA IE (odds ratio, 6.2; 95% confidence interval, 2.9-13.2). Patients in the United States were most likely to be hemodialysis dependent, to have diabetes, to have a presumed intravascular device source, to receive vancomycin, to be infected with MRSA, and to have persistent bacteremia (P<.001 for all comparisons). CONCLUSIONS: S aureus is the leading cause of IE in many regions of the world. Characteristics of patients with S aureus IE vary significantly by region. Further studies are required to determine the causes of regional variation.
CONTEXT: The global significance of infective endocarditis (IE) caused by Staphylococcus aureus is unknown. OBJECTIVES: To document the international emergence of health care-associated S aureus IE and methicillin-resistant S aureus (MRSA) IE and to evaluate regional variation in patients with S aureus IE. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational cohort study set in 39 medical centers in 16 countries. Participants were a population of 1779 patients with definite IE as defined by Duke criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to December 2003. MAIN OUTCOME MEASURE: In-hospital mortality. RESULTS: S aureus was the most common pathogen among the 1779 cases of definite IE in the International Collaboration on Endocarditis Prospective-Cohort Study (558 patients, 31.4%). Health care-associated infection was the most common form of S aureus IE (218 patients, 39.1%), accounting for 25.9% (Australia/New Zealand) to 54.2% (Brazil) of cases. Most patients with health care-associated S aureus IE (131 patients, 60.1%) acquired the infection outside of the hospital. MRSA IE was more common in the United States (37.2%) and Brazil (37.5%) than in Europe/Middle East (23.7%) and Australia/New Zealand (15.5%, P<.001). Persistent bacteremia was independently associated with MRSA IE (odds ratio, 6.2; 95% confidence interval, 2.9-13.2). Patients in the United States were most likely to be hemodialysis dependent, to have diabetes, to have a presumed intravascular device source, to receive vancomycin, to be infected with MRSA, and to have persistent bacteremia (P<.001 for all comparisons). CONCLUSIONS: S aureus is the leading cause of IE in many regions of the world. Characteristics of patients with S aureus IE vary significantly by region. Further studies are required to determine the causes of regional variation.
Authors: Batu K Sharma-Kuinkel; Yuling Wu; David E Tabor; Hoyin Mok; Bret R Sellman; Amy Jenkins; Li Yu; Hasan S Jafri; Thomas H Rude; Felicia Ruffin; Wiley A Schell; Lawrence P Park; Qin Yan; Joshua T Thaden; Julia A Messina; Vance G Fowler; Mark T Esser Journal: J Clin Microbiol Date: 2014-11-12 Impact factor: 5.948
Authors: B Zaloudíková; E Němcová; J Pol; Z Sorm; S Wurmová; K Novotná; M Vaněrková; V Holá; F Růžička; L Dušek; P Němec; T Freiberger Journal: Eur J Clin Microbiol Infect Dis Date: 2011-10-02 Impact factor: 3.267
Authors: José M Miró; José M Entenza; Ana Del Río; Maria Velasco; Ximena Castañeda; Cristina Garcia de la Mària; Marlyse Giddey; Yolanda Armero; Juan M Pericàs; Carlos Cervera; Carlos A Mestres; Manuel Almela; Carlos Falces; Francesc Marco; Philippe Moreillon; Asuncion Moreno Journal: Antimicrob Agents Chemother Date: 2012-05-29 Impact factor: 5.191
Authors: Daniel C DeSimone; Imad M Tleyjeh; Daniel D Correa de Sa; Nandan S Anavekar; Brian D Lahr; Muhammad R Sohail; James M Steckelberg; Walter R Wilson; Larry M Baddour Journal: Am Heart J Date: 2015-07-17 Impact factor: 4.749
Authors: McKenzie K Lehman; Jeffrey L Bose; Batu K Sharma-Kuinkel; Derek E Moormeier; Jennifer L Endres; Marat R Sadykov; Indranil Biswas; Kenneth W Bayles Journal: Mol Microbiol Date: 2015-01-16 Impact factor: 3.501